Background Australia introduced a national human papillomavirus (HPV) vaccination program for girls in 2007 and boys in 2013, achieving high coverage. We assessed HPV prevalence among men who have sex with women (MSW) and men who have sex with men (MSM) aged 18–35 years and examined program effects. Methods Between 2015–2018, men self-collected a penile or intra-anal swab for HPV genotyping. Vaccination status was confirmed with the National Register. HPV prevalence was examined by age groups and vaccination status. Results Prevalence of quadrivalent vaccine–targeted HPV types (6, 11, 16, 18) was 10.6% (95% confidence interval [CI], 8.7%–12.8%) in unvaccinated MSW and 10.7% (95% CI, 5.7%–19.3%) in vaccinated MSW (P = .96). Prevalence was 40.3% (95% CI, 36.0%–44.8%) in unvaccinated MSM and 29.9% (95% CI, 23.1%–37.8%) in vaccinated MSM (P = .02). Among those with confirmed doses, quadrivalent types were detected in 0% (95% CI, 0%–7.7%; n = 46) of men who had their first dose at 13–19 years and 37.2% (95% CI, 27.5%–47.8%; n = 94) in those who received their first dose at 20 years or older. Conclusions Our data demonstrate the importance of universal adolescent HPV vaccination to ensure MSM receive the same benefits as MSW.

中文翻译：

---

2015-2018 年澳大利亚 18-35 岁男性的人瘤病毒患病率，根据疫苗接种状况和性取向


背景 澳大利亚于 2007 年和 2013 年分别针对女孩和男孩推出了全国人瘤病毒 （HPV） 疫苗接种计划，实现了高覆盖率。我们评估了 18-35 岁男女同行为者 （MSW） 和男男性行为者 （MSM） 的 HPV 患病率，并检查了项目效果。方法 2015-2018 年间，男性自行采集或肛门内拭子进行 HPV 基因分型。疫苗接种状态已在国家登记册上确认。按年龄组和疫苗接种状况检查 HPV 患病率。结果未接种疫苗的 MSW 中四价疫苗靶向 HPV 类型 （6、11、16、18） 的患病率为 10.6% （95% 置信区间 [CI]，8.7%-12.8%），接种疫苗的 MSW 为 10.7% （95% CI，5.7%-19.3%） （P = .96）。未接种疫苗的 MSM 的患病率为 40.3% （95% CI，36.0%-44.8%），接种疫苗的 MSM 的患病率为 29.9% （95% CI，23.1%-37.8%） （P = .02）。在已确认剂量的人群中，在 13-19 岁时接种第一剂的男性中，0% （95% CI，0%–7.7%;n = 46） 检测到四价类型，在 20 岁或以上接受第一剂的男性中检测到 37.2% （95% CI，27.5%–47.8%;n = 94）。结论 我们的数据证明了普及青少年 HPV 疫苗接种的重要性，以确保 MSM 获得与 MSW 相同的益处。